Why Paragon Care (ASX:PGC) is doubling down on Asia’s aesthetics and medtech markets

Paragon Care Limited (ASX:PGC) is pursuing back-to-back acquisitions in Southeast Asia as part of a larger plan to reinvent its regional footprint and earnings profile. The Australian healthcare distribution company announced the acquisitions of PT Haju Medical Indonesia and the Somnotec Group in the span of five weeks, signalling a high-conviction move into aesthetic services and medtech distribution across high-growth Asian markets. With its share price down more than 41 percent over the past year and sentiment around small-cap healthcare names continuing to soften, the company is positioning these deals as a revenue- and margin-accretive reset heading into financial year 2026.

Paragon Care’s shares closed at A$0.29 on 1 December 2025, hovering close to their 52-week low of A$0.24. Despite delivering stable operational updates, the company has underperformed the broader ASX 200 index by over 43 percent and the Australian healthcare sector by nearly 20 percent over the past twelve months. The question now is whether this pivot toward Asia’s high-growth medical services sector can reframe the narrative and deliver on the accretive promise both acquisitions bring.

Paragon Care has confirmed that both transactions are expected to close before the end of January 2026. The management team, led by Chief Executive Officer Carmen Riley, has stated that the acquisitions will allow the group to build a truly pan-Asian platform capable of servicing original equipment manufacturers across multiple regional hubs including Thailand, Indonesia, Vietnam, the Philippines, and Japan.

How the Haju Medical acquisition positions Paragon Care in the Asian aesthetics value chain

On 1 December 2025, Paragon Care announced the proposed acquisition of 100 percent of the issued shares in PT Haju Medical Indonesia and Insightof Co., Ltd, together known as Haju Medical. The deal will be executed through its wholly-owned subsidiary Paragon Care Singapore Pte. Ltd. and is valued at A$70 million. An upfront payment of A$30 million will be made at completion, with the remaining consideration payable over a two-year period based on the achievement of EBITDA targets. The acquisition is still subject to customary conditions including merger filings and regulatory approvals in South Korea and Indonesia.

Haju Medical, founded in 2014, has become one of Indonesia’s leading providers of medical aesthetic products, marketing solutions, and expert-led training workshops. The company employs 103 staff, almost entirely based in Indonesia, and sources its products through a buying house in South Korea that ensures supply of premium aesthetic goods to the Indonesian market. Its model blends education-led sales with logistics integration, giving it a unique footprint in a fast-growing industry segment.

For the financial year ending 31 December 2024, Haju Medical reported revenue of A$30 million and EBITDA of A$7.7 million. These figures, based on internal management accounts, point to a strong earnings profile with healthy margins. Analysts tracking the healthcare services sector note that aesthetic medicine is one of the few areas within medical services that combines discretionary spending potential with high demand elasticity in emerging markets like Indonesia.

Paragon Care stated that the acquisition is highly complementary to its existing business in Thailand and aligns with its expansion strategy in other growth markets such as Vietnam, the Philippines, Australia and New Zealand. The company expects the transaction to be earnings accretive beginning in FY26, and confirmed that Haju Medical’s current Chief Executive Officer Jay Won will remain with the business to support integration and business continuity.

Why the Somnotec deal strengthens Paragon Care’s medtech and logistics capabilities

On 28 October 2025, Paragon Care also announced its agreement to acquire the Somnotec Group, a well-established distributor of medical devices and related technology across Southeast Asia. The acquisition will also be executed through Paragon Care Singapore Pte. Ltd. and includes Somnotec’s operations in Singapore, Malaysia, Indonesia, Thailand and the Philippines. The transaction value is based on an enterprise valuation of SGD 24 million, or approximately A$28.4 million, with A$18 million payable upfront and the remainder linked to EBITDA performance over the subsequent two years.

Somnotec, founded in 2003, serves several clinical segments including anaesthesia, critical care, cardiology, and respiratory homecare. The company employs over 90 people and is well-integrated into the hospital procurement ecosystem in Singapore and Malaysia. Paragon Care has positioned the acquisition as a way to consolidate its medtech distribution capabilities and scale its contract logistics vertical, particularly in regions where it has already established vendor relationships and warehousing capacity.

Somnotec reported revenue of A$40 million and EBITDA of A$5.6 million for the same financial year ending 31 December 2024. While the EBITDA margin is lower than that of Haju Medical, the strategic value lies in its regulatory experience, OEM partnerships, and customer base within hospital networks. Paragon Care expects the acquisition to be earnings accretive in FY26.

Importantly, Somnotec Chief Executive Officer Richard Saw has agreed to remain with the company for a minimum of two years post-completion, providing operational continuity and allowing Paragon Care to phase integration and technology upgrades across different markets.

How the combined transactions will be funded without adding stress to the balance sheet

To support the funding requirements of both acquisitions, Paragon Care has secured working capital facilities across multiple geographies. These include NZ$12 million (approximately A$10.6 million) in New Zealand and US$17 million (approximately A$26.1 million) in Thailand. These facilities, which were previously approved, will be deployed alongside surplus cash available within the Paragon Care group to meet the upfront consideration amounts for both the Haju and Somnotec transactions.

The combined outlay across both deals is estimated at approximately A$98.4 million, and the staged payment structure ensures that the financial risk is spread over a two-year horizon tied to performance benchmarks. Analysts believe this is a prudent move, as it allows Paragon Care to preserve liquidity while incentivizing continued operational excellence from the acquired teams.

As of the last reported period, Paragon Care had a market capitalization of A$480.04 million, with a price-to-earnings ratio of 24.17 and earnings per share of A$0.012. The company does not currently offer a dividend and has focused instead on reinvestment and expansion as its primary capital allocation strategy.

What institutional investors and sector analysts are watching for next

Investor sentiment remains subdued despite the strategic nature of the deals. Paragon Care’s shares are trading near the lower end of their 52-week range and have significantly underperformed broader benchmarks. The stock has also underperformed relative to peers in the Australian small-cap healthcare index, many of which have pivoted to capital preservation amid tighter credit and cost pressures.

That said, daily trading volumes for Paragon Care have remained relatively steady, averaging approximately 480,000 shares over the past month. This suggests that while institutional buying has paused, there is still consistent interest and liquidity at current levels.

Looking ahead, analysts will be focused on the pace of regulatory clearance for both acquisitions, the speed of integration, and the ability of the acquired entities to meet their EBITDA milestones. The company expects to close the Somnotec transaction by 15 December 2025, and the Haju Medical deal by 30 January 2026, subject to merger filings and change-of-control approvals in their respective jurisdictions.

Paragon Care’s management has also hinted at a broader roadmap that includes digital transformation initiatives and enhanced OEM servicing capabilities across Asia. A detailed guidance update for FY26 is expected by mid-2026, which may serve as a near-term catalyst for investors seeking greater clarity on the group’s revenue and margin trajectory.

What are the key takeaways from Paragon Care’s Asian expansion strategy and dual acquisitions?

• Paragon Care Limited has announced two major acquisitions in Southeast Asia—PT Haju Medical Indonesia and the Somnotec Group—as part of a broader strategy to expand its regional footprint and earnings base in FY26.

• The acquisition of Haju Medical, valued at A$70 million, deepens Paragon Care’s position in the fast-growing medical aesthetics sector in Indonesia, with integration support from founder and CEO Jay Won who will remain with the business.

• Somnotec, acquired for approximately A$28.4 million, brings a strong distribution network across Singapore, Malaysia, Indonesia, Thailand, and the Philippines, bolstering Paragon Care’s medtech and logistics verticals.

• Both acquisitions are structured with performance-linked earnouts and are expected to be earnings accretive in financial year 2026, with a combined FY24 EBITDA contribution of approximately A$13.3 million.

• Funding for both transactions is being supported by previously secured credit facilities across New Zealand and Thailand, along with internal cash reserves, allowing the company to avoid raising new equity or increasing leverage significantly.

• Despite these developments, Paragon Care’s share price remains down over 41 percent year-on-year, with underperformance against the ASX 200 and the broader healthcare sector weighing on investor sentiment.

• Analysts and investors will be closely monitoring regulatory approvals, integration timelines, and the FY26 earnings guidance update, which will offer deeper insight into whether Paragon Care can translate these acquisitions into long-term shareholder value.